Evidence map›Paper›PMID 39279703›Full record

ArticleCurrent gene therapy2025

DeepLCRmiRNA: A Hybrid Neural Network Approach for Identifying Lung Cancer-Associated miRNAs.

Nitao Cheng, Chen Chen, Junliang Liu, Xuanchun Wang, Ziqi Gao, Ming Mao, Jingyu Huang

Abstract read
PubMed Publisher
In one paragraph

Article in Current gene therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nitao ChengDepartment of Thoracic Surgery, Central South Hospital, Wuhan University, Wuhan, China.
Chen ChenDepartment of Biological Repositories, Zhongnan Hospital of Wuhan University, Wuhan, China.
Junliang LiuDepartment of Computer Science, Harbin Institute of Technology, Harbin, China.
Xuanchun WangSchool of Medicine and Health, Harbin Institute of Technology, Harbin, China.
Ziqi GaoSchool of Medicine and Health, Harbin Institute of Technology, Harbin, China.
Ming MaoDepartment of Thoracic Surgery, Central South Hospital, Wuhan University, Wuhan, China.
Jingyu HuangDepartment of Thoracic Surgery, Central South Hospital, Wuhan University, Wuhan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionLung cancer stands as one of the most prevalent malignant neoplasms, with microRNAs (miRNAs) playing a pivotal role in the modulation of gene expression, impacting cancer cell proliferation, invasion, metastasis, immune escape, and resistance to therapy.

methodsThe intricate role of miRNAs in lung cancer underscores their significance as biomarkers for early detection and as novel targets for therapeutic intervention. Traditional approaches for the identification of miRNAs related to lung cancer, however, are impeded by inefficiencies and complexities.

resultsIn response to these challenges, this study introduced an innovative deep-learning strategy designed for the efficient and precise identification of lung cancer-associated miRNAs. Through comprehensive benchmark tests, our method exhibited superior performance relative to existing technologies.

conclusionFurther case studies have also confirmed the ability of our model to identify lung cancer- associated miRNAs that have undergone biological validation.

Indexed as

Biomarkers, TumorDeep LearningLung NeoplasmsMicroRNAsNeural Networks, ComputerGene Expression Regulation, NeoplasticHumansBiomarkers, TumorMicroRNAscell proliferationCNNdeep learningLung cancermetastasis.miRNA

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.